Cases & Deals

  • Home
  • Practices
  • Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makers

Share

Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makers

March 2020

Clients Merck & Co., Inc.

Jones Day is representing Merck & Co., Inc. in Hatch-Waxman patent infringement actions against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.

In re Sugammadex, No. 2-20-cv-02576 (CCC) (MF) (consolidated) (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.